Tary Traore

3.0k total citations
11 papers, 315 citations indexed

About

Tary Traore is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tary Traore has authored 11 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tary Traore's work include Ubiquitin and proteasome pathways (7 papers), Protein Degradation and Inhibitors (6 papers) and Histone Deacetylase Inhibitors Research (3 papers). Tary Traore is often cited by papers focused on Ubiquitin and proteasome pathways (7 papers), Protein Degradation and Inhibitors (6 papers) and Histone Deacetylase Inhibitors Research (3 papers). Tary Traore collaborates with scholars based in United States, Japan and Canada. Tary Traore's co-authors include Michael A. Milhollen, Usha Narayanan, Erik Koenig, Mark Manfredi, James Garnsey, Allison Berger, Michael P. Thomas, Jie Yu, Lenny Dang and Mark Rolfe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Tary Traore

10 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tary Traore United States	4	262	124	51	51	40	11	315
Michael P. Thomas United States	4	334 1.3×	153 1.2×	37 0.7×	68 1.3×	51 1.3×	5	385
James Garnsey United States	4	444 1.7×	176 1.4×	87 1.7×	84 1.6×	61 1.5×	7	515
Valerie Morris United States	8	178 0.7×	108 0.9×	38 0.7×	70 1.4×	45 1.1×	16	311
Britta Lamottke Germany	7	300 1.1×	151 1.2×	84 1.6×	48 0.9×	33 0.8×	8	420
Alexandra Moros Spain	6	230 0.9×	137 1.1×	52 1.0×	63 1.2×	21 0.5×	9	382
Ildiko Grandal Canada	6	260 1.0×	190 1.5×	42 0.8×	61 1.2×	15 0.4×	10	376
Marion Refici United States	5	280 1.1×	133 1.1×	25 0.5×	18 0.4×	30 0.8×	8	354
Dalia Quwaider Spain	10	266 1.0×	90 0.7×	129 2.5×	121 2.4×	21 0.5×	14	357
Leutz Buon United States	10	241 0.9×	133 1.1×	113 2.2×	44 0.9×	22 0.6×	28	368
Scott E. Millman United States	6	234 0.9×	83 0.7×	54 1.1×	84 1.6×	14 0.3×	10	313

Countries citing papers authored by Tary Traore

Since Specialization

Citations

This map shows the geographic impact of Tary Traore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tary Traore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tary Traore more than expected).

Fields of papers citing papers by Tary Traore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tary Traore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tary Traore. The network helps show where Tary Traore may publish in the future.

Co-authorship network of co-authors of Tary Traore

This figure shows the co-authorship network connecting the top 25 collaborators of Tary Traore. A scholar is included among the top collaborators of Tary Traore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tary Traore. Tary Traore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Khattar, Mithun, Tary Traore, Kristin L. Horton, et al.. (2018). Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2. The Journal of Immunology. 200(Supplement_1). 122.29–122.29. 3 indexed citations

Traore, Tary, et al.. (2018). Abstract LB-294: Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2. Cancer Research. 78(13_Supplement). LB–294. 5 indexed citations

Barghout, Samir H., Parasvi S. Patel, Xiaoming Wang, et al.. (2017). TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML). Blood. 130(Suppl_1). 814–814.

Milhollen, Michael A., Tary Traore, Jessica J. Huck, et al.. (2015). Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel. Molecular Cancer Therapeutics. 14(12_Supplement_2). A164–A164. 2 indexed citations

Traore, Tary, Jojanneke H.J. Huck, Jie Shi, et al.. (2014). 255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models. European Journal of Cancer. 50. 85–85. 3 indexed citations

Milhollen, Michael A., Marc L. Hyer, Jeff Ciavarri, et al.. (2014). 561 Nonclinical characterization of the first in class investigational ubiquitin activating enzyme inhibitor MLN7243 in cellular and in vivo models of cancer in support of a phase I study. European Journal of Cancer. 50. 181–182. 1 indexed citations

Bahamón, Brittany, Feng Gao, B. M. J. Stringer, et al.. (2014). 231 Clinical pharmacodynamic assay development for the first in class investigational ubiquitin activating enzyme (UAE) inhibitor MLN7243. European Journal of Cancer. 50. 78–78. 1 indexed citations

Smith, Peter G., Tary Traore, Usha Narayanan, et al.. (2011). Azacitidine/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models. Blood. 118(21). 578–578. 23 indexed citations

Traore, Tary, James Garnsey, Allison Berger, et al.. (2011). Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.. Journal of Clinical Oncology. 29(15_suppl). 8594–8594. 5 indexed citations

10.

Milhollen, Michael A., Tary Traore, Michael P. Thomas, et al.. (2010). MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma. Blood. 116(9). 1515–1523. 270 indexed citations

11.

Traore, Tary, James Garnsey, Erik Koenig, et al.. (2009). Pre-Clinical Antitumor activity of MLN4924, An Inhibitor of NEDD8-Activating Enzyme (NAE), in a Novel Primary Human DLBCL Xenograft Model.. Blood. 114(22). 927–927. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact